MedTrace Logo

To Evaluate the Safety, Tolerability and Efficacy of R2R01 Combined With SOC as Compared to SOC Alone in Outpatients With Worsening Heart Failure (WHF)

NCT06264310 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2024-11-29

No results posted yet for this study

Summary

This Study Aims to Evaluate the Safety, Tolerability and Efficacy of R2R01 Combined With SOC as Compared to SOC Alone in Outpatients With Worsening Heart Failure (WHF)

Conditions

Interventions

DRUG

Placebo

Matching placebo SC injection

DRUG

R2R01

Pharmaceutical Form: sterile 2R vials containing 10 mg of R2R01 for SC injection.

Sponsors & Collaborators

  • International HealthCare, LLC

    collaborator OTHER

  • River 2 Renal Corp.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-01
Primary Completion
2024-11-04
Completion
2024-11-25
FDA Drug
Yes

Countries

  • United States
  • Germany
  • Italy

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06264310 on ClinicalTrials.gov